Background
Chronic kidney disease is common in people with HIV (PWH), with prevalence likely to rise as this population ages. Compared with tenofovir disoproxil fumarate–based antiretroviral regimens, tenofovir alafenamide (TAF)–based regimens have shown a superior renal safety profile, improving treatment options for PWH with renal impairment. Using pooled trial data, we assessed renal outcomes in PWH with mild to moderate renal impairment receiving bictegravir/emtricitabine/TAF (B/F/TAF).
Methods
Participant data from nine Phase 3/3b trials (NCT02607930, NCT02607956, NCT03547908, NCT02603120, NCT02603107, NCT02652624, NCT03110380, NCT03405935, NCT03631732) were pooled. Treatment-naïve or virologically suppressed adult PWH with Cockcroft-Gault estimated glomerular filtration rate (eGFR) ≥30–<90 mL/min at treatment initiation who received B/F/TAF for up to 5 years were included. We evaluated absolute eGFR and eGFR change from baseline, renal treatment-emergent adverse events (TEAEs), and treatment discontinuations due to renal TEAEs.
Results
Of 1069 participants, 975 had eGFR ≥60–<90 mL/min (Stage 2 eGFR), 86 had eGFR ≥45–<60 mL/min (Stage 3a eGFR), and 8 had eGFR ≥30–<45 mL/min (Stage 3b eGFR). Overall, 31% of included participants were female, 51% were White, and 8% were treatment naïve. Median (Q1, Q3) age was 53 (44, 60) years. Median (Q1, Q3) B/F/TAF exposure duration was 83.4 (52.4, 101.9) weeks, with 46 participants exposed for ≥240 weeks. Absolute eGFR remained stable from baseline to Week 96 for those with Stage 2 eGFR and Stage 3a eGFR (Figure, panel A). Median (Q1, Q3) eGFR (mL/min) change from baseline at Week 96 was 0.6 (-5.4, 6.6) overall; Stage 2, 0.1 (-5.8, 6.6); Stage 3a, 2.0 (-3.6, 5.7) (panel B). Absolute eGFR for Stage 2 participants was largely stable, with minimal change in eGFR from baseline to Week 240. Data for Stage 3b participants, and past Week 96 for those with Stage 3a eGFR, were limited by low participant numbers. Renal TEAEs occurred in 28 (2.6%) participants (most frequent: acute kidney injury [AKI] [n=10], decreased creatinine renal clearance [n=6], and proteinuria [n=5]). One participant with Stage 2 eGFR discontinued B/F/TAF treatment following AKI; the discontinuation was judged as unrelated to the study drug.
Conclusions
Among PWH with mild to moderate renal impairment, stable kidney function was observed in participants receiving B/F/TAF for up to 5 years. The overall rate of renal TEAEs was low, with only one discontinuation due to renal TEAEs.
Table or Figure